PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT • 2.1 Preface • 2.2 Preface • 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 04: PIPELINE ANALYSIS PART 05: MARKET SIZING • Market definition • Market sizing 2018 • Market size and forecast 2018-2023 PART 06: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 07: MARKET SEGMENTATION BY PRODUCT • Market segmentation by product • Comparison by product • Targeted therapy - Market size and forecast 2018-2023 • Chemotherapy - Market size and forecast 2018-2023 • Market opportunity by product PART 08: CUSTOMER LANDSCAPE PART 09: MARKET SEGMENTATION BY TYPE • Exocrine pancreatic cancer • Endocrine pancreatic cancer PART 10: GEOGRAPHIC LANDSCAPE • Geographic segmentation • Geographic comparison • Americas - Market size and forecast 2018-2023 • EMEA - Market size and forecast 2018-2023 • APAC - Market size and forecast 2018-2023 • Key leading countries • Market opportunity PART 11: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 12: MARKET TRENDS PART 13: VENDOR LANDSCAPE • Overview • Landscape disruption PART 14: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • Eli Lilly • F. Hoffmann-La Roche • Novartis • Pfizer • Shire PART 15: APPENDIX • Research methodology • List of abbreviations Exhibit 01: Years in consideration Exhibit 02: Global oncology therapeutics market Exhibit 03: Segments of global oncology therapeutics market Exhibit 04: Market characteristics Exhibit 05: Market segments Exhibit 06: Therapies in late stage development for pancreatic cancer Exhibit 07: Market definition - Inclusions and exclusions checklist Exhibit 08: Market size 2018 Exhibit 09: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 10: Global market: Year-over-year growth 2019-2023 (%) Exhibit 11: Five forces analysis 2018 Exhibit 12: Five forces analysis 2023 Exhibit 13: Bargaining power of buyers Exhibit 14: Bargaining power of suppliers Exhibit 15: Threat of new entrants Exhibit 16: Threat of substitutes Exhibit 17: Threat of rivalry Exhibit 18: Market condition - Five forces 2018 Exhibit 19: Product - Market share 2018-2023 (%) Exhibit 20: Comparison by product Exhibit 21: Targeted therapy - Market size and forecast 2018-2023 ($ millions) Exhibit 22: Targeted therapy - Year-over-year growth 2019-2023 (%) Exhibit 23: Chemotherapy - Market size and forecast 2018-2023 ($ millions) Exhibit 24: Chemotherapy - Year-over-year growth 2019-2023 (%) Exhibit 25: Market opportunity by product Exhibit 26: Customer landscape Exhibit 27: Market share by geography 2018-2023 (%) Exhibit 28: Geographic comparison Exhibit 29: Americas - Market size and forecast 2018-2023 ($ millions) Exhibit 30: Americas - Year-over-year growth 2019-2023 (%) Exhibit 31: EMEA - Market size and forecast 2018-2023 ($ millions) Exhibit 32: EMEA - Year-over-year growth 2019-2023 (%) Exhibit 33: APAC - Market size and forecast 2018-2023 ($ millions) Exhibit 34: APAC - Year-over-year growth 2019-2023 (%) Exhibit 35: Key leading countries Exhibit 36: Market opportunity Exhibit 37: Decision framework Exhibit 38: New drug approvals for pancreatic cancer Exhibit 39: Patent expiration dates for therapies for pancreatic cancer Exhibit 40: Impact of drivers and challenges Exhibit 41: Immunotherapy products under research Exhibit 42: Combination therapies for pancreatic cancer Exhibit 43: Vendor landscape Exhibit 44: Landscape disruption Exhibit 45: Vendors covered Exhibit 46: Vendor classification Exhibit 47: Market positioning of vendors Exhibit 48: Eli Lilly - Vendor overview Exhibit 49: Eli Lilly - Business segments Exhibit 50: Eli Lilly - Organizational developments Exhibit 51: Eli Lilly - Geographic focus Exhibit 52: Eli Lilly - Segment focus Exhibit 53: Eli Lilly - Key offerings Exhibit 54: F. Hoffmann-La Roche - Vendor overview Exhibit 55: F. Hoffmann-La Roche - Business segments Exhibit 56: F. Hoffmann-La Roche - Organizational developments Exhibit 57: F. Hoffmann-La Roche - Geographic focus Exhibit 58: F. Hoffmann-La Roche - Segment focus Exhibit 59: F. Hoffmann-La Roche - Key offerings Exhibit 60: Novartis - Vendor overview Exhibit 61: Novartis - Business segments Exhibit 62: Novartis - Organizational developments Exhibit 63: Novartis - Geographic focus Exhibit 64: Novartis - Segment focus Exhibit 65: Novartis - Key offerings Exhibit 66: Pfizer - Vendor overview Exhibit 67: Pfizer - Business segments Exhibit 68: Pfizer - Organizational developments Exhibit 69: Pfizer - Geographic focus Exhibit 70: Pfizer - Segment focus Exhibit 71: Pfizer - Key offerings Exhibit 72: Shire - Vendor overview Exhibit 73: Shire - Business segments Exhibit 74: Shire - Organizational developments Exhibit 75: Shire - Geographic focus Exhibit 76: Shire - Key offerings Exhibit 77: Validation techniques employed for market sizing Exhibit 78: List of abbreviations  

Eli Lilly F. Hoffmann-La Roche Novartis Pfizer Shire